Muhammad Furqan
4 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer (NCT04699838) | Muhammad Furqan | 2021-04-20 |
| PDR001 + Panobinostat for Melanoma and NSCLC (NCT03982134) | Muhammad Furqan | 2019-09-01 |
| Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy (NCT03951012) | Muhammad Furqan | 2019-04-15 |
Track Muhammad Furqan automatically
Every clearance here is in the API, with alerts when new ones post.